Drugs@FDA: FDA-Approved Drugs
Biologic License Application (BLA): 761091
Company: CELLTRION INC
Company: CELLTRION INC
Drug Name | Active Ingredients | Strength | Dosage Form/Route | Marketing Status | TE Code | RLD | RS |
---|---|---|---|---|---|---|---|
HERZUMA | TRASTUZUMAB-PKRB | 420MG | INJECTABLE;INJECTION | Prescription | None | No | No |
Original Approvals or Tentative Approvals
Action Date | Submission | Action Type | Submission Classification | Review Priority; Orphan Status | Letters, Reviews, Labels, Patient Package Insert | Notes | Url |
---|---|---|---|---|---|---|---|
12/14/2018 | ORIG-1 | Approval | N/A |
Label (PDF)
Letter (PDF) Review |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761091s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/761091Orig1s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761091Orig1s000TOC.cfm |
Supplements
Action Date | Submission | Supplement Categories or Approval Type | Letters, Reviews, Labels, Patient Package Insert | Note | Url |
---|---|---|---|---|---|
11/13/2024 | SUPPL-33 | Supplement |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761091s033lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/761091Orig1s033ltr.pdf | |
05/16/2019 | SUPPL-2 | Supplement |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761091s001s002lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/761091Orig1s001, s002ltr.pdf | |
05/16/2019 | SUPPL-1 | Supplement |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761091s001s002lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/761091Orig1s001, s002ltr.pdf |
Action Date | Submission | Supplement Categories or Approval Type | Letters, Reviews, Labels, Patient Package Insert |
Note | Url |
---|---|---|---|---|---|
11/13/2024 | SUPPL-33 | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761091s033lbl.pdf | ||
05/16/2019 | SUPPL-2 | Efficacy-New Indication | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761091s001s002lbl.pdf | |
05/16/2019 | SUPPL-1 | Manufacturing (CMC) | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761091s001s002lbl.pdf | |
12/14/2018 | ORIG-1 | Approval | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761091s000lbl.pdf |